Primary pulmonary hypertension - An update

Indian Heart Journal

Volumn 54, Issue 3, 2002, Pages 255-260

  Kothari, S S ^a   Bahl, V K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMLODIPINE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TEPROSTINIL; UNCLASSIFIED DRUG;

ANTICOAGULATION; CLINICAL TRIAL; CONTRACEPTION; DIET; EDITORIAL; HEPATITIS; HISTOPATHOLOGY; HUMAN; LUNG TRANSPLANTATION; OXYGEN THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BALLOON DILATATION; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION, PULMONARY; VASODILATOR AGENTS;

EID: 0036585010     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (60)

1. Primary pulmonary hypertension: A vascular biology and translational research "work in progress"
2. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
3. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
4. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family
5. Pathobiology of pulmonary hypertension. Extracellular matrix
6. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
7. Hemodynamic unloading leads to regression of pulmonary vascular disease in rats
8. Anorexigen induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lesson for the future in pathogenesis
9. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin
10. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension
11. Nocturnal hypoxemia is common in primary pulmonary hypertension
12. Medical therapy of pulmonary hypertension. Conventional therapies
13. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
14. Primary pulmonary hypertension: Natural history and the importance of thrombosis
15. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
16. Vasodilator therapy in primary pulmonary hypertension in children
17. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
18. Adenosine as a vasodilator in primary pulmonary hypertension
19. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
20. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension
21. Amlodipine for the treatment of pulmonary hypertension in children
22. Medical therapy of pulmonary hypertension. The prostacyclins
23. Optimal dose range of prostacyclin for patients with primary pulmonary hypertension
24. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
25. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double blind randomized controlled trial
26. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension
27. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
28. New treatments for pulmonary arterial hypertension
29. Long term treatment of pulmonary hypertension with aerosolized iloprost
30. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
31. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
32. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial
33. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary thromboembolic pulmonary hypertension
34. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension
35. Inhaled nitric oxide in neonates with persistent pulmonary hypertension
36. Long-term use of inhaled nitric oxide for pulmonary hypertension
37. Nitric oxide and endothelin-1 in pulmonary hypertension
38. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study
39. Bosentan in patients with pulmonary artery hypertension: A randomized, placebo controlled, multicenter study
40. Clinical efficacy of sitaxsentan, an endothelin receptor antagonist, in patients with pulmonary arterial hypertension: Open label pilot study
41. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
42. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
43. Sildenafil in primary pulmonary hypertension
44. Sildenafil ameliorates effects of inhaled nitric oxide withdrawl
45. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension
46. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension
47. Sildenafil from primary and secondary pulmonary hypertension
48. Atrial septostomy for pulmonary hypertension
49. Graded balloon atrial septostomy in severe pulmonary hypertension
50. Lung transplantation for primary pulmonary hypertension
51. Living donor single-lobe lung transplantation for primary pulmonary hypertension in a child
52. Successful reversal of pulmonary hypertension in Eisenmenger complex
53. Effects of thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
54. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension
55. Hemodynamic effects of levcromakalim in neonatal porcine pulmonary hypertension
56. Effect of aerosol heparin on the development of hypoxic pulmonary hypertension in the guinea pig
57. Pulmonary genetics, genomics and gene therapy: Conference summary
58. Progress in, and future prospects for, the treatment of primary pulmonary hypertension